Literature DB >> 8226158

Radioresponsiveness of human glioma, sarcoma, and breast cancer spheroids depends on tumor differentiation.

M Stuschke1, V Budach, H Sack.   

Abstract

PURPOSE: Differences in the intrinsic radiosensitivity within and between different tumor classes have been noticed for human tumor cell lines using the clonogenic assay. By far, most of the cell lines studied up to now were derived from poorly differentiated tumors. In this study, the influence of tumor differentiation on the radiation doses necessary to control 50% of small oxic spheroids (SCD50) was determined. Evidence of a distinct dependence of radioresponsiveness on tumor progression provides a background for an investigation of the underlying mechanisms. METHODS AND MATERIALS: Spheroids were aggregated from 1000-1500 cells in agarose coated 24 multi-well plates. Their diameters ranged from 156 to 405 microns, depending on the cell line. Spheroids were irradiated with graded 60Co single doses using spheroid control as end point and a minimum follow-up period of 3 months.
RESULTS: Cell lines from three low grade gliomas and 10 malignant gliomas were studied in the spheroid control assay. The group mean SCD50 values were 6.1 +/- 1.6 Gy and 13.1 +/- 3.3 Gy, respectively. Four cell lines from grade 2 soft tissue sarcomas had a mean SCD50 value of 6.2 +/- 0.5 Gy and one undifferentiated sarcoma line of 11.0 Gy. Three well-differentiated breast cancer lines expressed the cell adhesion molecule E-cadherin, had an epithelioid morphology in monolayer culture, were estrogen receptor positive or contact inhibited in multicellular spheroids. Two undifferentiated breast cancer lines had a fibroblastoid morphology and were marker negative. The mean SCD50 value of the former was 10.5 +/- 1.0 Gy while that of the undifferentiated lines was 14.8 +/- 2.8 Gy. Analysis of variance revealed a significant effect of the tumor type as well as the grade of dedifferentiation on the SCD50 after irradiation with one fraction or 2Gy/fraction. The surviving fractions at 2 Gy (SF2), obtained from the spheroid control rates after different fractionation schedules by approximation of the linear quadratic model assuming Poisson statistics were significantly dependent on tumor type (p = 0.001, ANOVA F-test) but not on tumor differentiation (p = 0.27). The alpha/beta ratios did not depend on tumor type (p = 0.08, ANOVA F-Test) but significantly increased with the grade of tumor cell dedifferentiation (p = 0.03).
CONCLUSION: The spheroid model is suitable for measuring the radioresponsiveness of differentiated cell lines with very low colony forming efficiencies. Tumor cell differentiation is an important factor for the radioresponsiveness and recovery capacity of human tumor cells.

Entities:  

Mesh:

Year:  1993        PMID: 8226158     DOI: 10.1016/0360-3016(93)90389-d

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  Effects of irradiation and cisplatin on human glioma spheroids: inhibition of cell proliferation and cell migration.

Authors:  Fabian Fehlauer; Martina Muench; Dirk Rades; Lukas J A Stalpers; Sieger Leenstra; Paul van der Valk; Ben Slotman; Ernst J Smid; Peter Sminia
Journal:  J Cancer Res Clin Oncol       Date:  2005-11-01       Impact factor: 4.553

Review 2.  Hypofractionated Radiotherapy as Adjuvant Treatment in Early Breast Cancer. A Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Wilfried Budach; Edwin Bölke; Christiane Matuschek
Journal:  Breast Care (Basel)       Date:  2015-08-19       Impact factor: 2.860

3.  DC electrical field-induced c-fos expression and growth stimulation in multicellular prostate cancer spheroids.

Authors:  H Sauer; J Hescheler; D Reis; H Diedershagen; W Niedermeier; M Wartenberg
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

4.  Differential S-phase progression after irradiation of p53 functional versus non-functional tumour cells.

Authors:  Friedo Zölzer; Tamare Mußfeldt; Christian Streffer
Journal:  Radiol Oncol       Date:  2014-11-05       Impact factor: 2.991

5.  Prospective single-arm study of 72 Gy hyperfractionated radiation therapy and combination chemotherapy for anaplastic astrocytomas.

Authors:  Takuma Nomiya; Kenji Nemoto; Toshihiro Kumabe; Yoshihiro Takai; Shogo Yamada
Journal:  BMC Cancer       Date:  2008-01-16       Impact factor: 4.430

6.  Concurrent hypofractionated radiotherapy and 5-Fluorouracil for advanced sarcomas of the bone.

Authors:  C Zambatis; J Skarlatos; M Koukourakis; L Kosma; A Giatromanolaki; K Beroukas; D Yannakakis
Journal:  Sarcoma       Date:  1998

7.  Boron neutron capture therapy induces cell cycle arrest and cell apoptosis of glioma stem/progenitor cells in vitro.

Authors:  Ting Sun; Zizhu Zhang; Bin Li; Guilin Chen; Xueshun Xie; Yongxin Wei; Jie Wu; Youxin Zhou; Ziwei Du
Journal:  Radiat Oncol       Date:  2013-08-06       Impact factor: 3.481

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.